Showing 7541-7550 of 10275 results for "".
- New from Coppertone®: Whipped Sunscreenhttps://practicaldermatology.com/news/new-from-coppertone-whipped-sunscreen/2458309/COPPERTONE® is rolling out new Whipped formula sunscreens. The new formulas are available in the CLEARLYSheer® and WaterBABIES® Pure & Simple line. “For my patients, one of the biggest barriers to using everyday su
- Certain Lifestyle Choices May Trump Genes When it Comes to Youthful Looking Skinhttps://practicaldermatology.com/news/certain-lifestyle-choices-may-trump-genes-when-it-comes-to-youthful-looking-skin/2458313/Nurture has a larger effect on exceptionally youthful skin appearance than nature, according to a new study by Olay done in collaboration with personal genetics company 23andMe. Specifically, sunscreen usage and
- Umbrellas Plus Sunscreen Needed to Stave Off Sunburnshttps://practicaldermatology.com/news/umbrellas-plus-sunscreen-needed-to-stave-off-sunburns/2458317/When it comes to preventing sunburns, neither beach umbrella or SPF 100 sunscreen are enough on their own, according to a new study in JAMA Dermatology that suggests both are needed for sufficient sun prote
- NeoStrata Debuts Exuviance AGE REVERSE Hand Rejuvenatorhttps://practicaldermatology.com/news/neostrata-debuts-exuviance-age-reverse-hand-rejuvenator/2458321/NeoStrata Company, Inc. is rolling out Exuviance AGE REVERSE Hand Rejuvenator, an intensive two-step peel. This 10% Citric Acid Peel gently exfoliates rough patches, uncovering smooth skin and preparing hands for the Exuviance AGE REVERSE Hand R
- L'Oréal Buys CeraVe, AcneFree and AMBI from Valeanthttps://practicaldermatology.com/news/loral-buys-cerave-acnefree-and-ambi-from-valeant/2458322/Valeant Pharmaceuticals International, Inc. is selling CeraVe, AcneFree and AMBI skincare brands to L'Oréal for $1.3 billion in cash. The transaction is expected to close in the first quarter of
- Menlo Begins Enrollment for Phase 2 Studies of NK-1 for Pruritushttps://practicaldermatology.com/news/menlo-begins-enrollment-for-phase-2-studies-of-nk-1-for-pruritus/2458325/Menlo Therapeutics Inc. has initiated enrollment in two new Phase 2 trials evaluating a novel neurokinin 1 (NK-1) receptor antagonist, serlopitant, for the treatment of pruritus associated with atopic dermatitis and for the treatment of pruritus fol
- Smart Hairbrush and Overachieving Mirrors Make Waves at CES 2017https://practicaldermatology.com/news/smart-hairbrush-and-overachieving-mirrors-make-waves-at-ces-2017/2458328/Beauty is getting a whole lot smarter, and more and more companies are getting in on the game. These are among the main takeaways from the BeautyTech Summit at the annual Consumer Electronics Show (CES), taking place in Las Vegas from Jan. 5-8, 2017. This is the be-all, end-all trade show
- Study Examines Diversity in Dermatologic Clinical Trialshttps://practicaldermatology.com/news/study-examines-diversity-in-dermatologic-clinical-trials/2458332/Dermatologic clinical trials within the United States reflect the growing diversity of the US population, but reporting of both sex and racial/ethnic diversity of research cohorts is still lacking, especially among studies conducted outside of the United States, according to a new report publishe
- Revance Starts Phase III Program for Injectable Toxin in Frown Lineshttps://practicaldermatology.com/news/revance-starts-phase-iii-program-for-injectable-toxin-in-frown-lines/2458330/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials follo
- National Psoriasis Foundation Awards 2016 Grants and Fellowshipshttps://practicaldermatology.com/news/national-psoriasis-foundation-awards-2016-grants-and-fellowships/2458334/The National Psoriasis Foundation (NPF) awarded more than $1.9 million in research funding in 2016, including 23 new projects from around the world. Established and emerging scientists received awards for their innovative work in advancing the research of p